comprehensive -WSS

comprehensive

author：comprehensive 2025-09-28 12:49:58 - browse：9

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Lab trade group sues FDA to halt regulation of lab

hotspot

WSS

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Focused ultrasound for uterine fibroids: an uphill battle

Focused ultrasound for uterine fibroids: an uphill battle

A pediatrician calls for Congress to pass the child tax credit deal

Pumping milk in bathrooms at health conferences is common

David Sabatini, ex

hotspot

comprehensive

Wikipedia

Supreme Court strikes down use of affirmative action

Medicare drug price lawsuits could be good politics for Biden

The high cost of giving birth even with insurance

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Drug repurposing or repositioning? The language matters

Heat waves linked to early deliveries, preterm births in new study

Heart attack and stroke risk calculators need revising

Stigma and the return of syphilis

As demand for Covid shots wanes, Moderna seeks its next success

What will save rural psychiatry services? Higher Medicaid payments

focus

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Immunocompromised patients offer clues on chronic Covid

Dana Farber says 6 studies to be retracted and 31 corrected

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Inaction leaves children at risk from dangerous chemotherapy drug

There's an unseen cost to disruptive road

entertainment

hotspot

hotspot

leisure time